News

Upcoming Conferences

CPhI 2017
Frankfurt, Germany
» Visit website

OCT, 2017
24-26

News & Press releases

DRGT announces results of Phase I study expanding clinical utility of the drug Sirolimus utilizing the company's novel Super-API technology platform

MSIDA, Malta, Oct. 05, 2017 - DRGT, a specialty pharmaceutical company, today announced the results of its Phase I study of DRGT18-2, a novel formulation of Sirolimus (Rapamune®), originally a Pfizer product approved by the FDA.

» Read more

DRGT’s novel Celecoxib composition – opportunity for low dose, immediate onset of pain relief with the only NSAID COX-2 inhibitor on the market

19th December 2016, Swatar, Malta - DRGT, a specialty pharmaceutical company announced today the Phase I clinical results of its DRGT-46 and DRGT-47 programs, new compositions of Celecoxib – a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). 

» Read more

Dr. Philip Kantoff - leading expert in clinical oncology and prostate cancer joins DRGT as Senior Clinical Advisor

14th December 2016, Malta - DRGT, a specialty pharmaceutical company announced today that Dr. Philip Kantoff joined the leadership as Senior Clinical Advisor to accelerate the progress of its ambitious oncology drug development program.

» Read more

DRGT’s novel Abiraterone Acetate composition provides opportunity for dose reduction and increased efficacy in prostate cancer

DRGT announced Phase I clinical results of its DRGT-45 program, a new composition of Abiraterone Acetate - a major drug in the fight against metastatic, castration-resistant prostate cancer.

» Read more

Quotient Clinical begins prostate cancer project for Druggability Technologies

June 23, 2015 - Quotient Clinical, the Translational Pharmaceutics® Company, initiates a new RapidFACT program for Druggability Technologies (DRGT) for evaluating enhanced formulations of abiratone acetate.

» Read more

Druggability Technologies enters into a strategic collaboration with Bayer HealthCare

DRGT signs a broad collaboration agreement with Bayer HealthCare to leverage DRGT’s Super-API Technology to accelerate the discovery and development of novel drugs.

» Read more